Physician profile
Zinabu Maxwell
NPI 1366616955
$3,062.43
in general payments reported to CMS, 2019-2025
28 companies · $22.54 in 2025
The $22.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $590 · 2021: $845 · 2022: $878 · 2023: $181 · 2024: $20.00 · 2025: $22.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $203 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.45 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.36 | 2021-2023 | |
| Pfizer INC. | $504.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $278.10 | 2019-2023 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $230.99 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.25 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $183.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $167.73 | 2019-2023 | Belsomra |
| Novo Nordisk INC | $158.84 | 2020-2023 | Ozempic, Rybelsus |
| Amgen INC. | $140.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.47 | 2019-2021 | |
| Lilly USA, LLC | $73.67 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.15 | 2019-2022 | |
| Redhill Biopharma INC. | $48.85 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $41.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.09 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.87 | 2022 | |
| Qol Medical, LLC | $28.45 | 2021 | |
| Seqirus USA INC | $25.29 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $24.38 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.01 | 2022 | |
| Abbott Laboratories | $21.98 | 2021 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Acerus Pharmaceuticals Corporation | $19.27 | 2022 | |
| Zealand Pharma US, INC. | $19.26 | 2021 | |
| Amarin Pharma, INC. | $16.48 | 2021 | |
| Astellas Pharma US INC | $14.63 | 2021 | |
| Allergan, INC. | $13.52 | 2020 | |
| Esperion Therapeutics, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zinabu Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.